Lista de obras - Marek Jarema - Dominio Público Uruguay

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder

artículo científico publicado en 2018

A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe

artículo científico publicado en 2017

A few facts from the history of selected biological treatment methods in psychiatry

artículo científico publicado en 2008

Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.

artículo científico publicado en 2011

Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?

artículo científico publicado en 2014

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

artículo científico

Antipsychotics in clinical practice. Treatment of the first schizophrenic episode

artículo científico publicado en 2008

Are we able to evaluate suicide risk?

artículo científico publicado en 2018

Atypical antipsychotics in the treatment of mood disorders

artículo científico publicado en 2007

Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics

artículo científico publicado en 2016

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

artículo científico publicado en 2016

Biological treatment of mental disorders

artículo científico publicado en 2008

Body Image and Body Experience Disturbances in Schizophrenia: an Attempt to Introduce the Concept of Body Self as a Conceptual Framework.

artículo científico publicado en 2016

CT and MRI white-matter lesions in Alzheimer's disease

Clinical determinants of mental disorders occurring during the infertility treatment

artículo científico publicado en 2015

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology

artículo científico

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics

artículo científico publicado en 2016

Current concepts of pharmacological treatment in schizophrenia

artículo científico publicado el 1 de noviembre de 2002

Cytokines, sleep and wakefulness regulation, and general health: a commentary to the review "The influence of cytokines on wakefulness regulation"

artículo científico publicado el 1 de junio de 2012

Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agents.

artículo científico publicado en 2014

Effects of cognitive remediation therapy versus other interventions on cognitive functioning in schizophrenia inpatients.

artículo científico publicado en 2017

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

artículo científico publicado en 2017

Elective cesarean section on psychiatric indications - the phenomenon analysis, report of two cases and psychiatric clinical recommendations

artículo científico publicado en 2016

Electroencephalographic theta activity and cognition in schizophrenia: preliminary results

artículo científico publicado en 2014

Eszopiclone in the treatment of insomnia

Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: The FEDORA project

artículo científico publicado en 2014

Fighting stigma of mental illness in midsize European countries

artículo científico

From the history of Polish psychiatry: paragnomen

Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype

artículo científico publicado en 2014

Guidelines for the use of second-generation long-acting antipsychotics

artículo científico publicado en 2015

Herbal drug treatment.

artículo científico publicado en 2008

Hypersomnia and cognitive impairment in a patient with bipolar disorder - a case report.

artículo científico publicado en 2017

Letter to Editor. In search of definition of the term "psychotic process" - thoughts and doubts

artículo científico publicado en 2017

Letter to the editors

artículo científico publicado en 2007

Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study

artículo científico publicado en 2004

Long-term pharmacotherapy aimed at maintaining abstinence or reducing alcohol intake in alcohol-dependent individuals. Guidelines from the Section of Pharmacotherapy of Polish Society for Research on Addictions (PTBU) and the Section of Psychopharmac

MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia

artículo científico publicado el 1 de marzo de 2012

Myth and reality of pragmatic trials.

artículo científico publicado en 2010

Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia-A Systematic Review

scientific article published on 16 August 2019

Oxytocin model of formation of psychotic symptoms and its implication for research concerning oxytocinergic pathway in schizophrenia

Oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia

artículo científico publicado en 2014

Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia

artículo científico publicado en 2017

Practical aspects of the use of ziprasidone in schizophrenia

artículo científico publicado el 1 de noviembre de 2010

Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial

artículo científico publicado el 1 de julio de 2003

Schizophrenia causes significant burden to patients' and caregivers' lives

artículo científico publicado en 2016

Schizophrenia plus – comorbidity of schizophrenia and personality disorders. Clinician’s reflections

Stigma in Midsize European Countries

Stigmatization of psychiatrists and general practitioners: results of an international survey.

artículo científico publicado en 2014

Strategies of long-term treatment of psychotic disorders.

artículo científico publicado en 2007

Subjective and objective evaluation of olanzapine treatment in schizophrenia

artículo científico publicado en 2004

The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties

artículo científico publicado en 2015

The Predictive Value of Psychopathological Subclassifications for the Neuroleptic Treatment Outcome in Schizophrenia ⬇️

artículo científico publicado el 1 de enero de 1991

The controversy around the diagnosis of selective mutism - a critical analysis of three cases in the light of modern research and diagnostic criteria

artículo científico publicado en 2018

The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial

artículo científico publicado en 2015

Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression

artículo científico publicado el 1 de julio de 2011

Treatment of depression in first episode of schizophrenia: results from EUFEST.

artículo científico publicado en 2012

Treatment patterns of schizophrenia based on the data from seven Central and Eastern European Countries

artículo científico publicado en 2016

Virtual reality – a valuable tool to advance treatment of mental disorders

Zespół psychoorganiczny — historia a współczesność

[Acute psychiatric diseases]

artículo científico publicado en 2007

[Androgens - a common biological marker of sleep disorders and selected sexual dysfunctions?]

artículo científico publicado en 2014

[Antipsychotics in clinical practice. The refractory schizophrenic patients treatment].

artículo científico publicado en 2008

[Between health and schizophrenia].

artículo científico publicado en 2013

[Cognitive dysfunctions in depression - underestimated symptom or new dimension?]

scientific article published on 01 November 2014

[Cognitive rehabilitation for people living with schizophrenia - the newest interventions]

scientific article published on 01 November 2014

[Pharmacological standards in schizophrenia treatment]

scientific article published on 01 November 2006

[Second generation antipsychotics: similarities and differences]

artículo científico publicado en 2003

[Second generation of neuroleptics--expectations and the reality]

scientific article published on 01 November 2002

[Sleep quality and daytime sleepiness in schizophrenia spectrum disorders during antipsychotic treatment]

artículo científico publicado en 2009

[The assessment of chosen psychometric features of B-CATS test battery in schizophrenia - preliminary report]

artículo científico publicado en 2014

[The change of quality of life and clinical picture in schizophrenia]

artículo científico publicado en 2002

Lista de obras de Marek Jarema

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder

A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern Europe

A few facts from the history of selected biological treatment methods in psychiatry

Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.

Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

Antipsychotics in clinical practice. Treatment of the first schizophrenic episode

Are we able to evaluate suicide risk?

Atypical antipsychotics in the treatment of mood disorders

Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics

Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

Biological treatment of mental disorders

Body Image and Body Experience Disturbances in Schizophrenia: an Attempt to Introduce the Concept of Body Self as a Conceptual Framework.

CT and MRI white-matter lesions in Alzheimer's disease

Clinical determinants of mental disorders occurring during the infertility treatment

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology

Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics

Current concepts of pharmacological treatment in schizophrenia

Cytokines, sleep and wakefulness regulation, and general health: a commentary to the review "The influence of cytokines on wakefulness regulation"

Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agents.

Effects of cognitive remediation therapy versus other interventions on cognitive functioning in schizophrenia inpatients.

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

Elective cesarean section on psychiatric indications - the phenomenon analysis, report of two cases and psychiatric clinical recommendations

Electroencephalographic theta activity and cognition in schizophrenia: preliminary results

Eszopiclone in the treatment of insomnia

Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: The FEDORA project

Fighting stigma of mental illness in midsize European countries

From the history of Polish psychiatry: paragnomen

Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype

Guidelines for the use of second-generation long-acting antipsychotics

Herbal drug treatment.

Hypersomnia and cognitive impairment in a patient with bipolar disorder - a case report.

Letter to Editor. In search of definition of the term "psychotic process" - thoughts and doubts

Letter to the editors

Long-term assessment of the efficacy and tolerability of risperidone in early schizophrenia: An international multicenter study

Long-term pharmacotherapy aimed at maintaining abstinence or reducing alcohol intake in alcohol-dependent individuals. Guidelines from the Section of Pharmacotherapy of Polish Society for Research on Addictions (PTBU) and the Section of Psychopharmac

MATRICS consensus cognitive battery--standard for the assessment of cognitive functions in clinical trials in schizophrenia

Myth and reality of pragmatic trials.

Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia-A Systematic Review

Oxytocin model of formation of psychotic symptoms and its implication for research concerning oxytocinergic pathway in schizophrenia

Oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia

Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia

Practical aspects of the use of ziprasidone in schizophrenia

Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial

Schizophrenia causes significant burden to patients' and caregivers' lives

Schizophrenia plus – comorbidity of schizophrenia and personality disorders. Clinician’s reflections

Stigma in Midsize European Countries

Stigmatization of psychiatrists and general practitioners: results of an international survey.

Strategies of long-term treatment of psychotic disorders.

Subjective and objective evaluation of olanzapine treatment in schizophrenia

The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties

The Predictive Value of Psychopathological Subclassifications for the Neuroleptic Treatment Outcome in Schizophrenia ⬇️

The controversy around the diagnosis of selective mutism - a critical analysis of three cases in the light of modern research and diagnostic criteria

The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial

Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression

Treatment of depression in first episode of schizophrenia: results from EUFEST.

Treatment patterns of schizophrenia based on the data from seven Central and Eastern European Countries

Virtual reality – a valuable tool to advance treatment of mental disorders

Zespół psychoorganiczny — historia a współczesność

[Acute psychiatric diseases]

[Androgens - a common biological marker of sleep disorders and selected sexual dysfunctions?]

[Antipsychotics in clinical practice. The refractory schizophrenic patients treatment].

[Between health and schizophrenia].

[Cognitive dysfunctions in depression - underestimated symptom or new dimension?]

[Cognitive rehabilitation for people living with schizophrenia - the newest interventions]

[Pharmacological standards in schizophrenia treatment]

[Second generation antipsychotics: similarities and differences]

[Second generation of neuroleptics--expectations and the reality]

[Sleep quality and daytime sleepiness in schizophrenia spectrum disorders during antipsychotic treatment]

[The assessment of chosen psychometric features of B-CATS test battery in schizophrenia - preliminary report]

[The change of quality of life and clinical picture in schizophrenia]

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder